2. Disease Areas
  3. Infection
  4. HIV Infection

HIV Infection

Acute HIV infection is a self-limited phase occurring within the first few weeks after initial exposure to the human immunodeficiency virus (HIV), marked by rapid viral replication, high viral loads, and nonspecific symptoms such as fever, rash, and lymphadenopathy. This stage may last from days to over 10 weeks, during which the immune system begins to mount a response. Early diagnosis is critical for initiating timely treatment and reducing transmission risk. HIV infection is associated with acquired immunodeficiency syndrome (AIDS) and has links to other infectious diseases like syphilis. The CCR5 gene plays a key role in HIV pathogenesis, and related biological pathways include the Innate Immune System and ERK Signaling. Drugs such as Candesartan cilexetil and Lercanidipine have been studied in this context. Affected tissues include T cells and breast tissue, with associated phenotypes involving cellular dysfunction and neoplastic changes.

 

HIV Infection (116):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-160229
    ssRNA40 sodium 98.34%
    ssRNA40 sodium (R-1075 sodium) is a single-stranded RNA40 derived from HIV-1. ssRNA40 sodium activates the TLR7, TLR8, TLR2, RIG-I, MDA5, MyD88, Caspase-3, IRE1α, NLRP3 inflammasome and IRF7 signaling pathways. ssRNA40 sodium alters mRNA expression in neutrophils, induces pro-inflammatory cytokines, ROS, autophagy (autophagy), pyroptosis (pyroptosis), neuronal death, neurodegeneration, aggregate formation and NK cell activation. ssRNA40 sodium activates the expression of CD62L, CD11b, CD69, MX1, OAS1, ATG7, LC3B and XBP1 in immune cell and neuronal populations. ssRNA40 sodium causes cortical neuron loss and axonal damage in mice in a TLR7-dependent manner. ssRNA40 sodium can be used in research on HIV-1 infection, neurodegeneration, COVID-19 and HIV-associated neurological disorders.
    ssRNA40 sodium
  • HY-W020658
    L-α-Phosphatidylinositol 97281-52-2
    L-α-Phosphatidylinositol is a type of phospholipid. L-α-Phosphatidylinositol can serve as an antigen in ELISA assays for screening antiphospholipid antibodies. L-α-Phosphatidylinositol can be used in studies related to HIV-1 infection.
    L-α-Phosphatidylinositol
  • HY-W037893
    CHMA1004 dihydrochloride 122323-88-0 99.38%
    CHMA1004 (Methyl piperazine-2-carboxylate; METTL3 activator-1) dihydrochloride is a METTL3/METTL14/WTAP methyltransferase complex activator. CHMA1004 dihydrochloride exhibits neuroprotective and anxiolytic potential by enhancing m6A methylation modification of RNA. CHMA1004 dihydrochloride promotes HIV replication in an infection context. CHMA1004 dihydrochloride can be used in studies related to anxiety disorders and HIV-1 infection.
    CHMA1004 dihydrochloride
  • HY-125474
    Carrageenan 9000-07-1
    Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice.
    Carrageenan
  • HY-18257
    Rolitetracycline 751-97-3 ≥98.0%
    Rolitetracycline is a highly soluble, broad-spectrum antibiotic derived from tetracycline. Rolitetracycline binds to and stabilizes bovine serum albumin, and also inhibits HIV-1 integrase, blocks Aβ fibril formation and suppresses dengue virus proliferation. Rolitetracycline mediates the inhibition of Aβ fibrils via a specific three-dimensional pharmacophore conformation, and exerts bacteriostatic and bactericidal activities. Rolitetracycline acts synergistically with Penicillin G (HY-N7139) or Cephalothin (HY-B1275A) to alter the effects on microbial growth. Rolitetracycline serves as an important tool compound for the study of bacterial infections (urinary tract infections, sepsis), HIV-1 and dengue virus infections, as well as Alzheimer's disease.
    Rolitetracycline
  • HY-114506
    trans-​2-​Methoxycinnamic acid 1011-54-7 99.83%
    trans-2-Methoxycinnamic acid (Compound 6) is a trans-cinnamic acid (HY-N0610) derivative. trans-2-Methoxycinnamic acid inhibits α-glucosidase with an IC50 of 4.34 mM. trans-2-Methoxycinnamic acid can be used in the research of HIV infection and hyperglycemia.
    trans-​2-​Methoxycinnamic acid
  • HY-181231
    PROTAC CDK9 degrader-12 3052648-82-2
    PROTAC CDK9 degrader-12 is a selective CDK9 PROTAC degrader with a DC50 of 23 nM. PROTAC CDK9 degrader-12 induces proteasome-dependent degradation of CDK9, blocks CDK9-mediated HIV-1 transcriptional elongation, and reduces HIV-1 RNA synthesis. PROTAC CDK9 degrader-12 is applicable to research related to HIV-1 infection.
    PROTAC CDK9 degrader-12
  • HY-179634
    ASF-006 sodium
    ASF-006 sodium, a tetrapodal tryptophan derivative, is a potent viral invasion inhibitor. ASF-006 sodium shows potent antiviral activity against different SARS-CoV-2 Omicron variants but not against the ancestral SARS-CoV.2 strain (Wuhan-Hu-1). ASF-006 sodium competitively inhibits receptor-binding domain (RBD)-ACE2 binding via an allosteric mechanism. ASF-006 sodium inhibits Omicron BA.1, Omicron XBB.1.5, respiratory syncytial virus (RSV) and Ebola virus infection with IC50s of 0.02 μM, 0.3 μM, 1.52 μM and 0.2 μM, respectively. ASF-006 sodium inhibits cell entry of both HIV and enterovirus A71[1].
    ASF-006 sodium
  • HY-P991069
    VRC-01 1412901-55-3 99.805%
    VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection.
    VRC-01
  • HY-W012166
    N-Succinimidyl bromoacetate 42014-51-7 99.20%
    N-Succinimidyl bromoacetate (NHS-Bromoacetate) is a heterobifunctional crosslinking reagent, mainly used to modify the ɛ-amino group of lysine side chains. By covalently linking its bromoacetyl moiety to the ɛ-amino group of lysine in peptidomimetics, N-Succinimidyl bromoacetate enables their conjugation with thiol-modified nanoparticles via thioether bonds. N-Succinimidyl bromoacetate also performs bromoacetylation modification on carrier proteins, which then forms stable thioether bonds with the thiol groups of cysteine in peptides, thus efficiently preparing soluble peptide-protein conjugates with high substitution ratios. N-Succinimidyl bromoacetate can be used to prepare activated Sepharose derivatives for affinity chromatography, protein affinity labeling reagents, and peptide-protein immunogen conjugates with non-immunogenic linkages. N-Succinimidyl bromoacetate is applicable to studies related to HIV-1 infection and glioblastoma multiforme.
    N-Succinimidyl bromoacetate
  • HY-W010937
    1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide 174899-83-3 99.91%
    1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (BMIM-TFSI; BMI-TFSI) is an HIV-1 integrase inhibitor. 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide weakly inhibits recombinant HIV-1 integrase 3'-processing or strand transfer activity. 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide can be used for the research of HIV-1.
    1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide
  • HY-D0976
    NF279 202983-32-2 98.5%
    NF279 is a selective P2X1 receptor antagonist and NTPDase inhibitor, with a P2X1 IC50 value of 19 nM. NF279 suppresses GABA-evoked currents, reduces ATP-excited respiratory activity, alters hypoglossal nerve burst parameters, and blocks CXCR4, CCR5, CXCR3, and CXCR7-mediated calcium responses. NF279 arrests HIV-1 fusion downstream of CD4 binding, inhibits R5- and X4-tropic HIV-1 strains. NF279 can be used for the research of HIV-1 infection.
    NF279
  • HY-142989
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine 99296-81-8 ≥98.0%
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is a polyunsaturated phospholipid that serves as a component of lipid monolayers and small unilamellar vesicles. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine can be used to prepare endoplasmic reticulum-targeted liposomes (PERLs), which are composed of 1,2-didocosahexaenoyl-sn-glycero-3-phosphoethanolamine, l-α-phosphatidylinositol and l-α-phosphatidylserine at a molar ratio of 1.5:1.5:1:1. PERLs reduce cholesterol levels in human peripheral blood mononuclear cells (PBMCs) and decrease HIV-1 particle secretion from HIV-1-infected PBMCs. Liposomes formed from 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine exhibit cytotoxicity against leukemia cells. 1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine is applicable to studies related to hepatitis C virus infection, HIV infection, hepatitis B virus infection and leukemia.
    1,2-Didocosahexaenoyl-sn-glycero-3-phosphocholine
  • HY-P4076
    MPG peptides, Pβ 791642-10-9 98.26%
    MPG peptides, Pβ is an amphipathic cell-penetrating peptide. MPG peptides, Pβ consists of three components: the hydrophobic fusion sequence (GALFLGFLGAAGSTMGA) of HIV glycoprotein 41, a spacer domain (WSQP), and the nuclear localization signal (KKKRKV) of the large T antigen of Simian virus 40. MPG peptides, Pβ can form stable non-covalent complexes with nucleic acids (including DNA) through electrostatic interactions and improve their intracellular delivery. MPG peptides, Pβ can be used in studies of HIV-1-related immune responses.
    MPG peptides, Pβ
  • HY-N2188
    Beta-Acetoxyisovalerylshikonin 69091-17-4 99.57%
    Beta-Acetoxyisovalerylshikonin is a naturally occurring naphthoquinone-type shikonin derivative that is widely distributed in the roots and cell suspension cultures of *Arnebia euchroma*, *Arnebia guttata*, *Onosma hispidum* and *Lithospermum erythrorhizon*. Beta-Acetoxyisovalerylshikonin exhibits favorable antibacterial, anti-inflammatory, wound-healing promoting and antioxidant activities, and also possesses potential anti-tumor and anti-HIV properties.
    Beta-Acetoxyisovalerylshikonin
  • HY-110354
    UCM05 1094451-90-7 99.22%
    UCM05 (G28UCM) is a fatty acid synthase (FASN) and filamentous temperature-sensitive protein Z (Ftsz) inhibitor. UCM05 inhibits fatty acid synthesis, viral replication, and Gram-positive bacterial growth. UCM05 binds to FtsZ GTP-binding sites, inhibits GTPase activity, and disrupts Z-ring localization. UCM05 can be used for the research of HSV-1/2 infection, HIV-1 infection, and Gram-positive bacterial infections[1][2][3].
    UCM05
  • HY-N7543
    Schisantherin D 64917-82-4 99.66%
    Schisantherin D is a lignan. Schisantherin D can be isolated from Kadsura interior. Schisantherin D downregulates the expression of ETBR and inhibits the secretion of ECM and ET-1. Schisantherin D alleviates EtOH + ET-1-induced hepatocyte cytotoxicity. Schisantherin D potently inhibits HIV replication in cells.
    Schisantherin D
  • HY-111964A
    Lenacapavir sodium 2283356-12-5 99.86%
    Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection.
    Lenacapavir sodium
  • HY-W112938
    TMPyP tetrachloride 92739-63-4 98.30%
    TMPyP tetrachloride is a DNA-binding agent, singlet oxygen Sensitizer and photobleaching agent. TMPyP tetrachloride binds to DNA via intercalation or external groove complexation; irradiation induces its photoinduced release from DNA. TMPyP tetrachloride sensitizes the generation of singlet molecular oxygen upon irradiation, and prolonged irradiation leads to photobleaching. TMPyP tetrachloride initially localizes preferentially in neuronal nuclei and cytoplasm, and irradiation triggers its subcellular relocalization. TMPyP tetrachloride binds to K+ -free single-molecule G4-DNA nanowires via intercalation, and binds to K+ -type variants via non-intercalation. TMPyP tetrachloride can be used in studies related to cancer, HIV infection and bacterial infection.
    TMPyP tetrachloride
  • HY-125183
    BMS-818251 2974489-09-1 99.36%
    BMS-818251 is a HIV-1 attachment and entry inhibitor. BMS-818251 binds to HIV-1 Env gp120, interferes with viral attachment and entry processes, and inhibits HIV-1 viral replication. BMS-818251 can be used in studies related to HIV-1 infection.
    BMS-818251